134 related articles for article (PubMed ID: 31347926)
21. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Kaku K
J Diabetes Investig; 2020 Jan; 11(1):132-141. PubMed ID: 31197929
[TBL] [Abstract][Full Text] [Related]
22. Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Kashiwagi A; Sakatani T; Nakamura I; Akiyama N; Kazuta K; Ueyama E; Takahashi H; Kosakai Y
Endocr J; 2018 Jul; 65(7):693-705. PubMed ID: 29848902
[TBL] [Abstract][Full Text] [Related]
23. Real-world evidence for long-term safety and effectiveness of ipragliflozin in treatment-naïve versus non-naïve Japanese patients with type 2 diabetes mellitus: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
Maegawa H; Tobe K; Nakamura I; Uno S
Diabetol Int; 2021 Oct; 12(4):430-444. PubMed ID: 34567926
[TBL] [Abstract][Full Text] [Related]
24. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study).
Kaku K; Naito Y; Senda M; Kurihara Y; Gunji R; Kakiuchi S; Utsunomiya K
J Diabetes Investig; 2020 Mar; 11(2):405-416. PubMed ID: 31390166
[TBL] [Abstract][Full Text] [Related]
25. Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
Kadowaki T; Haneda M; Ito H; Sasaki K; Matsukawa M; Yamada Y
Adv Ther; 2020 Mar; 37(3):1065-1086. PubMed ID: 31873865
[TBL] [Abstract][Full Text] [Related]
26. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
Kadowaki T; Inagaki N; Watada H; Sasaki K; Mori-Anai K; Iwasaki T; Teranishi T
Adv Ther; 2022 Apr; 39(4):1642-1658. PubMed ID: 35138572
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
[TBL] [Abstract][Full Text] [Related]
28. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
Utsunomiya K; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Koshida R; Kameda H; Tamura M; Kaku K
J Diabetes Investig; 2020 Jul; 11(4):906-916. PubMed ID: 32034997
[TBL] [Abstract][Full Text] [Related]
29. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Koshida R; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Kaku K
J Diabetes Investig; 2021 Feb; 12(2):184-199. PubMed ID: 32597517
[TBL] [Abstract][Full Text] [Related]
30. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
Tanaka A; Murohara T; Taguchi I; Eguchi K; Suzuki M; Kitakaze M; Sato Y; Ishizu T; Higashi Y; Yamada H; Nanasato M; Shimabukuro M; Teragawa H; Ueda S; Kodera S; Matsuhisa M; Kadokami T; Kario K; Nishio Y; Inoue T; Maemura K; Oyama J; Ohishi M; Sata M; Tomiyama H; Node K;
Cardiovasc Diabetol; 2016 Sep; 15(1):133. PubMed ID: 27619983
[TBL] [Abstract][Full Text] [Related]
31. Ipragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes.
Kutoh E; Wada A; Murayama T; Hirate M
Drug Res (Stuttg); 2016 Jul; 66(7):345-50. PubMed ID: 27056638
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Safety and Efficacy of Sitagliptin for Type 2 Diabetes Mellitus in Japan: Results of a Multicentre, Open-Label, Observational Post-Marketing Surveillance Study.
Yoshikawa K; Tsuchiya A; Kido T; Ota T; Ikeda K; Iwakura M; Maeda Y; Maekawa S
Adv Ther; 2020 May; 37(5):2442-2459. PubMed ID: 32306246
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.
Kaku K; Isaka H; Sakatani T; Toyoshima J
Diabetes Obes Metab; 2019 Oct; 21(10):2284-2293. PubMed ID: 31173455
[TBL] [Abstract][Full Text] [Related]
34. Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
Nakamura I; Maegawa H; Tobe K; Uno S
Diabetes Ther; 2021 May; 12(5):1359-1378. PubMed ID: 33730336
[TBL] [Abstract][Full Text] [Related]
35. Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL): A 12-week interim analysis.
Utsunomiya K; Shimmoto N; Senda M; Kurihara Y; Gunji R; Kameda H; Tamura M; Mihara H; Kaku K
J Diabetes Investig; 2016 Sep; 7(5):755-63. PubMed ID: 27181254
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials.
Chen W; Li P; Wang G; Chen Y; Wang B; Chen M
Postgrad Med; 2019 Nov; 131(8):578-588. PubMed ID: 31414934
[No Abstract] [Full Text] [Related]
37. Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan.
Goda M; Yamakura T; Sasaki K; Tajima T; Ueno M
Curr Med Res Opin; 2018 Feb; 34(2):319-327. PubMed ID: 29025285
[TBL] [Abstract][Full Text] [Related]
38. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.
Kashiwagi A; Kazuta K; Goto K; Yoshida S; Ueyama E; Utsuno A
Diabetes Obes Metab; 2015 Mar; 17(3):304-8. PubMed ID: 24919820
[TBL] [Abstract][Full Text] [Related]
39. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Han KA; Chon S; Chung CH; Lim S; Lee KW; Baik S; Jung CH; Kim DS; Park KS; Yoon KH; Lee IK; Cha BS; Sakatani T; Park S; Lee MK
Diabetes Obes Metab; 2018 Oct; 20(10):2408-2415. PubMed ID: 29862619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
